NEJM: HPV vaccination and cervical cancer risk.

Studies have shown the efficacy of the four-priced human papillomavirus (HPV) vaccine in preventing advanced cervical lesions.
, however, there is a lack of data on the relationship between titration HPV vaccination and the subsequent risk of leaching cervical cancer.
a recent study published in the top medical journal NEJM, researchers followed 1672,983 girls and women between the ages of 10 and 30 between 2006 and 2017 using Sweden's National Registry of Demographics and Health.
researchers assessed the association between HPV vaccination and risk of indented cervical cancer, adjusting the age, year, county of residence, and parental characteristics of follow-up, including education, family income, the country of birth of the mother and the history of maternal disease.
, the researchers followed girls and women with cervical cancer at age 31.
was diagnosed with cervical cancer in 19 women who received the four-price HPV vaccine and 538 women who were not vaccinated.
of women who have been vaccinated, the cumulative incidence of cervical cancer is 47 per 100,000 and 94 per 100,000 unvaccinated women.
adjusting the age of follow-up, the incidence ratio of cervical cancer was 0.51 (95% confidence interval (CI) was 0.32 to 0.82) compared to the unvaccinated population.
, the incidence of cervical cancer was 0.37 (95% CI was 0.21 to 0.57) after additional adjustments to other covariances.
After correcting all covariations, the rate of occurrence was 0.12 (95% CI 0.00 to 0.34) among women vaccinated before the age of 17 and 0.47 (95% CI was 0.27 to 0.75) among women vaccinated between the ages of 17 and 30.
, it can be seen that in girls and women between the ages of 10 and 30, the risk of indulging cervical cancer can be significantly reduced.
.